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all cases of CDI with onset during hospitalization or within 72 hours after patient discharge. We subsequently undertook a search of all microbiologically confirmed cases of CDI during the period [2007] [2008] [2009] [2010] [2011] [2012] . Individuals who shared the same surname or same address were identified for additional investigation. All putative case-pairs identified were reviewed to identify potential epidemiological associations; this included ribotyping of available C. difficile isolates and, when possible, multiple-locus variable number tandem repeat analysis (MLVA). Six cases of paired CDI were identified.
In pair 1, the index patient, a 74-year-old woman, was admitted for investigation and management of diarrhea. She had had an episode of CDI earlier that year and received a diagnosis of recurrent CDI during this hospitalization. A specimen obtained within 1 day of admission to the hospital was found to be positive for glutamate dehydrogenase (GDH) and C. difficile toxin. One week later, the patient's husband (also her main caregiver) developed CDI. The contact patient had multiple comorbidities and his own independent risk factors for CDI. Isolates from both patients were identified as ribotype 027, and they were indistinguishable on MVLA typing.
In pair 2, the index patient, a 76-year-old woman, was admitted to the hospital for investigation of suspected acute colitis after chemotherapy. A stool sample obtained at hospital admission was found to be positive for GDH but negative for C. difficile toxin, which suggested C difficile colonization rather than CDI. However, because of persistent symptoms, the patient was given metronidazole therapy, to which she responded well. Her husband, a patient with chronic lung disease who required recurrent antibiotic therapy for infective exacerbations in the community, was admitted to the hospital 10 days later with diarrhea. A stool sample obtained the following day was positive for both GDH and C. difficile toxin. Both isolates belonged to ribotype 127.
In pair 3, a 39-year-old woman received a diagnosis of CDI in the community after receiving antibiotic therapy for presumed cholecystitis. Her 15-month-old son presented to his primary care physician with diarrhea. At the family's request, a stool sample was tested and was found to be positive for both GDH and C. difficile toxin. Ribotyping of the isolates demonstrated that both belonged to ribotype 017.
Review of the paired cases of CDI, taken together with indistinguishable ribotypes and their temporal association, is highly suggestive of an epidemiological link and thus highlights the potential for spread within families. Interestingly, 2 of 3 contact patients had their own independent risk factors for CDI. In addition, the apparent transmission from a GDHpositive but toxin-negative patient to her spouse, who went on to develop active CDI, is also of particular note. Although the clinical significance of isolating C. difficile in an infant is not clear, as in the last case-pair, the matching ribotypes suggest a putative link between the 2 cases.
A recent study has suggested that intrafamilial transmission of CDI is infrequent. 1 Our findings corroborate this. We identified 3 case-pairs from a total of 238 confirmed cases of CDI over a 5-year period. However, the database search relied on identification of shared surname and address, and this may have underestimated the frequency of transmission. Nevertheless, we have amended the information on CDI given to patients and their relatives. In particular, we have reinforced the importance of adopting appropriate hand hygiene measures by index case patients and family members (both at home and in the hospital) in an attempt to reduce the risk of intrafamilial spread of CDI.
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East North Central Region Has the Highest Prevalence of Vancomycin-Resistant Enterococcus faecalis in the United States
To the Editor-We read the article of Hayakawa et al 1 with great interest. The report describes the growing prevalence of vancomycin-resistant Enterococcus faecalis in Michigan, a state that also has the most reports of vancomycin-resistant Staphylococcus aureus. Similar findings were reported in the tigecycline evaluation and surveillance trial (TEST). The antimicrobial susceptibility data were obtained from the Surveillance Network Database (Eurofins-Medinet). The data are described in detail elsewhere 3 and have been widely used to characterize regional and national trends in antibiotic susceptibility. [4] [5] [6] [7] The 287 microbiological laboratories in the network were selected on the basis of geographic and demographic criteria to be representative of hospitals at the level of US Census Bureau regional divisions. Participating sites are required to submit reports for all bacterial isolates for which species identification and antibiotic sensitivities are recorded. Categorical susceptibility results are based on the Clinical Laboratory Standards Institute criteria adopted by the facility at the time of testing and reflect results as they were reported to the treating physician.
The analysis considered all outpatient and inpatient (including inpatient, outpatient, intensive care unit, and longterm care) isolates reported between January 1999 and July 2010 that were identified as E. faecalis. Perirectal surveillance cultures were not included in the database, and the data were filtered to retain only isolates that were tested to vancomycin. We then looked at the national and regional proportion of isolates that were reported as resistant to vancomycin throughout the study period.
Overall, in the East North Central region, a total of 44,108 isolates of E. faecalis between 1999 and 2010 were tested to vancomycin, of which 8.8% ( ) were resistant to n p 3,858 vancomycin. At the national level, the pooled proportion of vancomycin-resistant E. faecalis for 1999-2010 was 3.6% (13,022 of 354,462 E. faecalis isolates). The Northeast region was behind the East North Central region, with 5.2% of the E. faecalis isolates resistant to vancomycin (for yearly national and regional trends, see Figure 1 ). Figure 1 also indicates a steady rise in the proportion of vancomycin-resistant E. faecalis isolates in the United States, from 2.7% in 1999 to 3.9% in 2010.
Even though our results do not indicate a continuous rise in the proportion of vancomycin-resistant E. faecalis isolates from 1999 to 2010 in the East North Central region, the regional proportions have always been high compared with the national average. The proportion of vancomycin-resistant E. faecalis isolates in this region remained twice the national average during the 1999-2010 period. Eight of the 13 cases of vancomycin-resistant S. aureus were reported from southeast Michigan, an area approximately at the center of this region. 8 Coupled with evidence of the horizontal transfer of the vanA gene complex from vancomycin-resistant E. faecalis to S. aureus, 9,10 our findings underscore the importance of monitoring the trends in vancomycin-resistant E. faecalis through continuous and timely surveillance. Potential conflicts of interest. All authors report no conflicts of interest
